A number of existing pharmaceutical drugs and compounds under development may be effective against the Middle East Respiratory Syndrome, researchers have found.
In the first study, researchers screened a library of 290 pharmaceutical drugs, either FDA-approved or in advanced clinical development for antiviral activity against the MERS coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture. They found 27 compounds that were active against both viruses including some cancer drugs and antipsychotics.
Patient-to-nurse Infection of Coronavirus: First Proof
The World Health Organization said that two Saudi health workers have contracted the deadly coronavirus from patients, marking the first evidence of transmission in a hospital setting.
Advertisement
Matthew Frieman of the University of Maryland Medical School said repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to the normal paradigm of huge library screening against a specific viral enzyme.
He said given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the best solution to rapidly identify therapeutics for outbreaks due to emerging viruses.
![Saudi Confirms 61 MERS Coronavirus Death Toll]( "Saudi Confirms 61 MERS Coronavirus Death Toll")
With the death of an elderly woman from the MERS coronavirus, the death toll from the respiratory disease in Saudi Arabia has risen to 61 Saudi health authorities said.
In the second study, researchers collaborating in the European antiviral research program SILVER used a similar methodology to screen a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. They identified four compounds that inhibited MERS-CoV, SARS-CoV and Human Coronavirus 229E at relatively low concentrations.
Two of the compounds were also identified by the U.S. study: the antimalarial drug chloroquine and the antipsychotic chlorpromazine.
The third and final study finds that an experimental compound, previously shown to block SARS-CoV replication, can inhibit replication of two other coronaviruses, MERS-CoV and mouse hepatitis virus.
The study has been published online in the journal Antimicrobial Agents and Chemotherapy.
Source: ANI
Saudi Confirms 61 MERS Coronavirus Death Toll
With the death of an elderly woman from the MERS coronavirus, the death toll from the respiratory disease in Saudi Arabia has risen to 61 Saudi health authorities said.
Advertisement
In the second study, researchers collaborating in the European antiviral research program SILVER used a similar methodology to screen a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. They identified four compounds that inhibited MERS-CoV, SARS-CoV and Human Coronavirus 229E at relatively low concentrations.
Two of the compounds were also identified by the U.S. study: the antimalarial drug chloroquine and the antipsychotic chlorpromazine.
The third and final study finds that an experimental compound, previously shown to block SARS-CoV replication, can inhibit replication of two other coronaviruses, MERS-CoV and mouse hepatitis virus.
The study has been published online in the journal Antimicrobial Agents and Chemotherapy.
Source: ANI
Coronavirus Claims the Lives of 2 More in Saudi Arabia
The total number of fatalities have now reached 44, with 2 more women dying of the coronavirus MERS in Saudi Arabia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Coronavirus News
In Alzheimer's disease patients, COVID-19 infection may exacerbate cognitive symptoms, including brain fog.
COVID-19 patients receiving early convalescent plasma treatment are less likely to develop post-COVID (long COVID) with SARS-CoV-2 antibodies.
Discussions gain traction on the resurgence of masks and limited lockdowns this winter amid rising COVID variants.
India stands prepared to develop vaccines for any new COVID strain, as stated by Indian Council of Medical Research (ICMR).
While ongoing efforts in public awareness can curb COVID-19 resurgences, the lessons learned can shape a resilient and prepared global community.
